CA3036984C - Use of pridopidine for treating rett syndrome - Google Patents
Use of pridopidine for treating rett syndrome Download PDFInfo
- Publication number
- CA3036984C CA3036984C CA3036984A CA3036984A CA3036984C CA 3036984 C CA3036984 C CA 3036984C CA 3036984 A CA3036984 A CA 3036984A CA 3036984 A CA3036984 A CA 3036984A CA 3036984 C CA3036984 C CA 3036984C
- Authority
- CA
- Canada
- Prior art keywords
- pridopidine
- composition
- subject
- bdnf
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662395854P | 2016-09-16 | 2016-09-16 | |
| US62/395,854 | 2016-09-16 | ||
| PCT/US2017/051803 WO2018053280A1 (en) | 2016-09-16 | 2017-09-15 | Use of pridopidine for treating rett syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3036984A1 CA3036984A1 (en) | 2018-03-22 |
| CA3036984C true CA3036984C (en) | 2023-07-18 |
Family
ID=61619744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3036984A Active CA3036984C (en) | 2016-09-16 | 2017-09-15 | Use of pridopidine for treating rett syndrome |
Country Status (13)
| Country | Link |
|---|---|
| EP (2) | EP3512506B1 (https=) |
| JP (1) | JP6977029B2 (https=) |
| CN (1) | CN109982686A (https=) |
| AU (1) | AU2017326013B2 (https=) |
| BR (1) | BR112019005040A2 (https=) |
| CA (1) | CA3036984C (https=) |
| DK (2) | DK3512506T3 (https=) |
| ES (2) | ES2909557T3 (https=) |
| HU (1) | HUE058314T2 (https=) |
| IL (1) | IL265342B2 (https=) |
| MX (1) | MX388845B (https=) |
| PL (2) | PL4005570T3 (https=) |
| WO (1) | WO2018053280A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| PE20160195A1 (es) | 2013-06-21 | 2016-05-14 | Teva Pharmaceuticals Int Gmbh | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington |
| WO2018039475A1 (en) | 2016-08-24 | 2018-03-01 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for treating dystonias |
| ES3025836T3 (en) | 2016-08-24 | 2025-06-09 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for treating functional decline |
| ES2909557T3 (es) | 2016-09-16 | 2022-05-09 | Prilenia Neurotherapeutics Ltd | Utilización de la pridopidina para el tratamiento del síndrome de Rett |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| EP3920924A4 (en) | 2019-02-04 | 2022-11-16 | Prilenia Neurotherapeutics Ltd. | LOW-DOSE PRIDOIDIN FOR THE TREATMENT OF PARKINSON'S DISEASE AND OTHER PARKINSONIC-RELATED DISEASES |
| CN116472043A (zh) * | 2020-10-20 | 2023-07-21 | 普瑞尼亚神经治疗有限公司 | 普利多匹定和类似物用于治疗焦虑和抑郁的用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| CA2584831C (en) | 2004-10-13 | 2013-09-17 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
| SG188298A1 (en) | 2010-09-03 | 2013-04-30 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| MX347209B (es) * | 2011-12-08 | 2017-04-19 | Teva Pharmaceuticals Int Gmbh | La sal de bromhidrato de pridopidina. |
| HK1206297A1 (en) | 2012-04-04 | 2016-01-08 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for combination therapy |
| PE20160195A1 (es) | 2013-06-21 | 2016-05-14 | Teva Pharmaceuticals Int Gmbh | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington |
| PE20161220A1 (es) * | 2014-01-22 | 2016-11-23 | Teva Pharmaceuticals Int Gmbh | Formulaciones de pridopidina de liberacion modificada |
| WO2016138135A1 (en) * | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| EP4282479A3 (en) * | 2015-02-25 | 2024-02-21 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| ES2909557T3 (es) | 2016-09-16 | 2022-05-09 | Prilenia Neurotherapeutics Ltd | Utilización de la pridopidina para el tratamiento del síndrome de Rett |
-
2017
- 2017-09-15 ES ES17851614T patent/ES2909557T3/es active Active
- 2017-09-15 HU HUE17851614A patent/HUE058314T2/hu unknown
- 2017-09-15 EP EP17851614.2A patent/EP3512506B1/en active Active
- 2017-09-15 BR BR112019005040A patent/BR112019005040A2/pt not_active Application Discontinuation
- 2017-09-15 WO PCT/US2017/051803 patent/WO2018053280A1/en not_active Ceased
- 2017-09-15 PL PL22150695.9T patent/PL4005570T3/pl unknown
- 2017-09-15 CA CA3036984A patent/CA3036984C/en active Active
- 2017-09-15 AU AU2017326013A patent/AU2017326013B2/en active Active
- 2017-09-15 DK DK17851614.2T patent/DK3512506T3/da active
- 2017-09-15 CN CN201780071045.XA patent/CN109982686A/zh active Pending
- 2017-09-15 PL PL17851614T patent/PL3512506T3/pl unknown
- 2017-09-15 MX MX2019003069A patent/MX388845B/es unknown
- 2017-09-15 ES ES22150695T patent/ES2986807T3/es active Active
- 2017-09-15 EP EP22150695.9A patent/EP4005570B1/en active Active
- 2017-09-15 DK DK22150695.9T patent/DK4005570T3/da active
- 2017-09-15 JP JP2019514217A patent/JP6977029B2/ja active Active
-
2019
- 2019-03-13 IL IL265342A patent/IL265342B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL3512506T3 (pl) | 2022-05-30 |
| IL265342A (en) | 2019-05-30 |
| JP2019532926A (ja) | 2019-11-14 |
| EP4005570B1 (en) | 2024-05-15 |
| MX388845B (es) | 2025-03-20 |
| HUE058314T2 (hu) | 2022-07-28 |
| JP6977029B2 (ja) | 2021-12-08 |
| AU2017326013A1 (en) | 2019-04-11 |
| EP3512506A4 (en) | 2020-05-27 |
| CN109982686A (zh) | 2019-07-05 |
| ES2909557T3 (es) | 2022-05-09 |
| DK4005570T3 (da) | 2024-08-19 |
| PL4005570T3 (pl) | 2024-09-23 |
| BR112019005040A2 (pt) | 2019-07-16 |
| AU2017326013B2 (en) | 2020-12-24 |
| EP3512506B1 (en) | 2022-01-26 |
| WO2018053280A1 (en) | 2018-03-22 |
| DK3512506T3 (da) | 2022-04-19 |
| ES2986807T3 (es) | 2024-11-12 |
| IL265342B2 (en) | 2023-06-01 |
| EP4005570A1 (en) | 2022-06-01 |
| EP3512506A1 (en) | 2019-07-24 |
| CA3036984A1 (en) | 2018-03-22 |
| MX2019003069A (es) | 2019-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3036984C (en) | Use of pridopidine for treating rett syndrome | |
| Quinn et al. | PINK1/PARKIN signalling in neurodegeneration and neuroinflammation | |
| US11221329B2 (en) | Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity | |
| AU2018342072B2 (en) | Use of fenfluramine formulation in reducing number and frequencies of convulsive seizures in patient populations | |
| US20190247333A1 (en) | Method of reduction in convulsive seizure frequency | |
| JP2010510314A (ja) | 精神遅滞、ダウン症候群、脆弱ｘ症候群および自閉症の治療方法 | |
| KR20160037169A (ko) | 레트 증후군 및 그를 위한 치료 | |
| WO2019067413A1 (en) | USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS | |
| US20240398778A1 (en) | Use of pridopidine for treating rett syndrome | |
| AU2021383325B2 (en) | Use of pridopidine and analogs for treating rett syndrome | |
| Badadhe et al. | Huntington disease: brief overview | |
| HK40009961B (en) | Use of pridopidine for treating rett syndrome | |
| CN108601772A (zh) | 用于治疗tdp-43蛋白质病的他克莫司 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190314 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240726 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240726 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250702 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250702 |